Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

This study looks at how a medicine called **benralizumab** affects the lungs of people with severe eosinophilic asthma. 🫁 Eosinophilic asthma is a type of asthma with high levels of a type of white blood cell called eosinophils that can make breathing harder. Patients will be observed over a **48-week treatment period**. During this time, doctors will check for changes in the lung's structure and function. The study is for adults aged **18 to 70 years** who have been on certain asthma medications. Eligible participants must have persistent asthma symptoms despite using inhaled corticosteroids (ICS) and long-acting B2-agonists (LABA). After the treatment, there is a **4-week follow-up period**.

• **Time:** 48-week treatment + 4-week follow-up
• **Eligibility:** Adults 18-70 with severe eosinophilic asthma
• **Exclusions:** Current smokers, pregnant women, recent use of certain medicines